Yogesh Vaishnav

Dr. Yogesh Vaishnav


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2020 in Journal of Heterocyclic Chemistry
Verified
Journal Article
Closed access
PDF file
YVYogesh Vaishnav
Yogesh Vaishnav
DDDhansay Dewangan
Dhansay Dewangan
SVShekhar Verma
Shekhar Verma
AMAchal Mishra
Achal Mishra
ATAlok Singh Thakur
Alok Singh Thakur
SVSantosh Kumar Verma
Santosh Kumar Verma

1 November 2023 in Current Drug Safety
Verified
Journal Article
Closed access
PDF file
PSPreeti Singh
Preeti Singh
YVYogesh Vaishnav
Yogesh Vaishnav
SVShekhar Verma
Shekhar Verma
The drugs are projected to cure, prevent and treat diseases; however, there are also chances of mild or severe adverse drug reactions (ADRs) in the patients. Pharmacovigilance (PV) enhances the approach to safe medicines and healthcare, but integration into public healthcare remains a challenge in many countries. The Pharmacovigilance Programme of India (PvPI) is a nationwide programme launched by the Ministry of Health and Family Welfare (MoHFW), Government of India, on 14 July 2010. It is currently run by the Indian Pharmacopoeia Commission (IPC). Presently, 567 ADR Monitoring Centres (AMC) are functioning under PvPI across India. The Central Drugs Standard Control Organization (CDSCO), under the Directorate General of Health Services (DGHS), and the Ministry of Health, Family & Welfare (MoHFW) Government of India is the National Regulatory Authority (NRA) of India. This review aims to trace the development of PV in India and its status among the top ADR reporting countries, with a focus on the current status of the studied ADR in different regions in India. Among the top 20 countries enthusiastic about sending ICSR per million population between 2015 and 2020, India shares 2% of the total ICSRs in VigiBase. India is now being recognized as a hub of global clinical trials and clinical research studies. Hence, it is the need of the hour in India to have a dynamic PV network system with an efficient and prudent operation method. Nevertheless, in India, PV programs are at an early stage on par with other countries, and only because of underreporting of ADRs. However, in the future, PvPI may appear as a big dashboard for ADR reporting culture in India as it continuously works hard to improve patients and drug safety.

24 December 2022 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
YVYogesh Vaishnav
Yogesh Vaishnav
LBLaxmi Banjare
Laxmi Banjare
SVShekhar Verma
Shekhar Verma
GSGovind Sharma
Govind Sharma
DBDeepak Biswas
Deepak Biswas
KMKavya Manjunath
Kavya Manjunath
World is facing a new pandemic called covid-19SARS-CoV-2) since a year ago. Unfortunately there is no treatment for Covid 19 nowadays as well as no potential therapies has been developed to overcome from coronavirus pandemic. Some potential drug molecules with combination have ability to respond for covid19 virus. From the research it was found that the reduction of viral load can be treated with hydroxychloroquine and azithromycin combination. We evaluate the mode of interactions of hydroxychloroquine and azithromycin with the dynamic site of SARS-CoV-2 coronavirus main protease. Molecular Structure-based computational approach viz. molecular docking simulations were performed to scale up their affinity and binding fitness of the docked complex of novel SARS-CoV-2 coronavirus protease and hydroxychloroquine and azithromycin. The natural inhibitor N3 of novel SARS-CoV-2 coronavirus protease were exhibited highest affinity in terms of MolDock score (-167.203Kcal/mol), and hydroxychloroquine was found with lowest target affinity (-55.917 Kcal/mol).The amino acid residue cysteine 145 and histidine 41 is bound covalently and formed hydrogen bond interaction with SARS-CoV-2 inhibitor known as inhibitor N3 as such, hydroxychloroquine and azithromycin also formed hydrogen bond interaction. The binding patterns of the inhibitor N3 of SARS-CoV-2 coronavirus main protease could be used as a guideline for medicinal chemist to explore their SARS-CoV-2 inhibitory potential.

1 April 2026 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Open access
GTGajendra S. Thakur
Gajendra S. Thakur
AGAjay K. Gupta
Ajay K. Gupta
YVYogesh Vaishnav
Yogesh Vaishnav
SASivakumar Annadurai
Sivakumar Annadurai
SJSanmati K. Jain
Sanmati K. Jain
Introduction: Heterocyclic compounds are widely utilized in the development of anticancer medications due to their diverse structures and ability to interact with multiple biological targets within cancer cells. Quinoline is a heterocyclic compound and an essential compound in the domains of industrial and pharmaceutical chemistry because of its various pharmacological effects. Researchers are developing new traditional, synthetic, and innovative green approaches to synthesize mono- or poly-substituted quinoline derivatives for anticancer activity. Methods: A comprehensive literature survey was conducted using multiple databases, including Google Scholar, PubMed, SpringerLink, ScienceDirect, and others, to investigate the existing literature on synthetic strategies for various quinoline derivatives. This review article intends to present a summary of various traditional synthetic methods alongside innovative green approaches. Results: Many researchers have demonstrated that quinoline derivatives can be synthesized using various methods, including traditional techniques, hybrid approaches with heterocyclic structures, and innovative green synthetic methods, as well as elucidating their structure-activity relationships for potential use as anticancer agents. The majority of traditional synthetic methods rely on hazardous chemicals, low reaction rates, high temperatures, and high pressures. Currently, the green chemistry approach produces eco-friendly, economical, highyield, pure, and outstanding products in the fields of industry and pharmaceuticals. Discussion: This section explores various affordable and eco-friendly synthetic techniques that produce potent and specific quinoline compounds, intended for use as anticancer agents. Conclusion: The progress demonstrated in the green synthetic methods and the development of quinoline-based compounds as new treatment options could aid in identifying new and effective quinoline derivatives for cancer treatment in the future.

4 January 2026 in Discover Chemistry
Verified
Journal Article
Open access
PDF file
DVDeepshikha Verma
Deepshikha Verma
BABharti Ahirwar
Bharti Ahirwar
YVYogesh Vaishnav
Yogesh Vaishnav
Background In India and in various regions of Central Asia and Africa, one of the most prevalent deadly and painful hematological disorders is sickle cell anemia, which is a major concern because of less social awareness and no curative treatment available. Disease-carrying individuals have shorter life spans with high morbidity and mortality. To treat and manage the root cause of this disease, novel drug discovery is a necessity. Objective To identify best analogue of proposed derivative of 3,4 di-hydroxycinnamic acid which inhibits hemoglobin polymerization and useful for treatment of Sickle cell Disease. Method A series of analogues were created to determine docking scores of compounds utilizing Auto-Dock Vina software, and later redocking was done by other software to validate the best docked compound. Comparative analysis of binding energies and ADMET profiles of compounds with approved drugs was done to identify the best candidate, and to check stability, in silico simulation studies were performed to determine which would be the most effective, stable, and least hazardous compound. These were then synthesized and biologically assessed. Result We assessed that among the 14 analogues, the C-1 analogue exhibited superior binding affinities after using three software programs for molecular docking analysis. Additionally, MD simulation studies predicted better stability, as most residues in the RMSF were below 4.0 Å, with one base peak at the start and a larger peak observed at 2.0 Å. The radius of gyration remained within the range of 5.2 to 6.0 complex throughout the time period of the 100 ns simulation. Molecular dynamic simulation analysis shows that the complex remains stable all through the action, and the least toxic, better pharmacokinetic profile was assayed through ADMET software and later synthesized in the wet lab, and the newly synthesized compound was confirmed through IR, NMR, and mass data analysis, which also showed better anti-polymerizing activity confirmed through sickle cell-carrying human blood and normal human blood studies; the antioxidant activity of the compound is also confirmed by assay. Conclusion The best activity was shown by Compound C-1 by inhibiting the polymerization of RBCs and having antioxidant activity with a good pharmacokinetic profile than already existing USFDA drugs. Research Highlights Only symptomatic treatment management of drugs is available still. In this study, a novel analogue of 3,4-dihydroxycinnamic acid is showing better results as an anti-sickling activity by inhibiting polymerization of haemoglobin than the already existing approved drug for management of sickle cell anaemia, as it is one of the prevalent genetic hemoglobinopathies. Results are validated through molecular docking studies, molecular dynamic studies, and synthesis of the best compound. Further animal toxicity studies are reported, and anti-sickling activity is shown through human blood studies.

3 November 2025 in Archiv der Pharmazie
Verified
Journal Article
Closed access
RGRaksha Gupta
Raksha Gupta
AKAnubhuti Koshle
Anubhuti Koshle
SVSantosh Kumar Verma
Santosh Kumar Verma
KAKamal
Kamal
SVShekhar Verma
Shekhar Verma
KRKadalipura P. Rakesh
Kadalipura P. Rakesh